Various updates have been shared on biotech firm
Cencora. Despite a recent pullback in share price, Cencora has acquired
EyeSouth's retina business in a $1.1 billion deal contributing to its strategic growth. Nevertheless, investors showed cautious response towards the firm's OneOncology integration leading to a 3.3% fall in shares. The firm's
Q1 earnings topped estimates though the share price momentum cooled down subsequently. Keeping this backdrop, many wonder if it's time to reassess Cencora post-46% one year rally. The firm's expansion into rare disease services through
Curant collaboration is also noteworthy while Cencora's recent acquisition of Alliance Healthcare reported to deepen its global reach. Other developments include a price target update from
JPMorgan, retirement of its CFO, and an affirmed EPS of $17 despite a leadership shake-up. The company's stock rose as it expanded its retina network and diversified its service offerings prompting many analysts to raise predictions for the Future. However, critics counter that a high P/E ratio puts a bullish growth narrative to test. Despite this, Cencora's resilience amidst challenges, positions it as a top growth and value stock for the long-term.
Cencora COR News Analytics from Fri, 15 Aug 2025 07:00:00 GMT to Fri, 10 Apr 2026 23:46:26 GMT -
Rating 4
- Innovation -6
- Information 5
- Rumor -5
